Devyser Diagnostics AB

As of June 30, 2026, Devyser Diagnostics AB carries a market capitalization of 1.45B, placing it among publicly traded companies globally. Its enterprise value stands at 1.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Devyser Diagnostics AB's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Devyser Diagnostics AB has 16.89M shares outstanding.

As of June 30, 2026, Devyser Diagnostics AB trades at a trailing price-to-earnings ratio of 73.71. The price-to-sales ratio is 5.47, and the price-to-book ratio stands at 3.80.

As of June 30, 2026, Devyser Diagnostics AB trades at an EV/EBITDA multiple of 25.57 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 53.16 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.41B versus a market cap of 1.45B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Devyser Diagnostics AB maintains a current ratio of 2.92, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.02, indicating elevated leverage, while an interest coverage ratio of 7.68 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Devyser Diagnostics AB posted a return on equity (ROE) of 5.45, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.27 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.10, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.19, useful for judging operating efficiency across full business cycles. The company generates approximately 2.18M in revenue per employee across its workforce of 120.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.27 indicates how many times Devyser Diagnostics AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Devyser Diagnostics AB recorded 4.60M in income tax expense. That works out to an effective tax rate of 19.17, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 24.00M, leaving 19.40M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Devyser Diagnostics AB's stock has declined approximately 63.66% over the past 52 weeks. The 50-day moving average sits at 55.18, while the 200-day moving average is 78.30.

Over the twelve months ended June 30, 2026, Devyser Diagnostics AB generated 261.40M in revenue and converted that into 19.40M in net income, yielding earnings per share of 1.16. EBITDA reached 55.30M, while operating income came in at 26.50M.

As of June 30, 2026, Devyser Diagnostics AB holds 81.00M in cash and equivalents against 45.80M in total debt, resulting in a net debt position of -80.80M. Total book value stands at 381.00M, with working capital of 135.40M providing operational flexibility.

Devyser Diagnostics AB produced 38.70M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -60.30M in capital expenditures, free cash flow totaled -21.60M - equivalent to -1.30 per share.

Over the twelve months ended June 30, 2026, Devyser Diagnostics AB posted a gross margin of 80.45, reflecting its pricing power and cost economics. The operating margin of 10.14 and net profit margin of 7.42 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.51: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.06, meaning Devyser Diagnostics AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Devyser Diagnostics AB has an Altman Z-Score of 8.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.